Allarity Therapeutics surges on positive trial data for breast cancer therapy

Allarity Therapeutics

05/07/2023 16:24

** Shares of Allarity Therapeutics Inc  ALLR.O  soar 61.9%
to $10.24
    ** Stock, Nasdaq Composite's  .IXIC  top pct. gainer, is set
for record one-day pct. jump, if gains hold     
    ** Co says its breast cancer therapy showed potential for
improved clinical benefit in four patients evaluated in a
mid-stage study in Europe 
    ** The patients were selected using co's proprietary
companion diagnostics, which helps identify people who can
benefit the most from the therapy
     ** The treatment, ixabepilone, was originally developed by
Bristol Myers Squibb  BMY.N  and is approved for metastatic
breast cancer patients in the U.S under the brand name Ixempra  
 
    ** ALLR has the exclusive rights for the development and
commercialization of Ixempra in Europe - ALLR
    ** Including session gains, stock down ~97% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))